Groundbreaking Rare Disease Drug Approval (OGSIVEO [nirogacestat]) Propelled by Expert Regulatory Strategy and Program Management

Rare Disease Drug Approval (OGSIVEO [nirogacestat])

To translate the regulatory strategy into essential actionable elements, clients rely on program management to create outcome-driven plans to execute as a team efficiently and effectively. This can sometimes take years of cooperation, collaboration, and incremental progress. Perseverance and teamwork pay off. Read our case study, written in collaboration with our colleagues at SpringWorks.